H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients

Clinical and Experimental Immunology

Volumn 157, Issue 1, 2009, Pages 83-89

  Schlapbach, L J ^a,b   Aebi, C ^a,b   Hansen, A G ^c   Hirt, A ^b   Jensenius, J C ^c   Ammann, R A ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b Department of Pediatrics   (Switzerland)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Bacteraemia; Cancer; Fever and neutropenia; H ficolin; Innate immunity

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; FICOLIN;

ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CHILD; FEMALE; FEVER; FLUOROMETRY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

ADOLESCENT; BACTEREMIA; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; FEMALE; FEVER; FLUOROIMMUNOASSAY; GLYCOPROTEINS; HUMANS; LECTINS; MALE; NEOPLASMS; NEUTROPENIA; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 66849128425     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.03957.x     Document Type: Article

References (40)

1. Walsh TJ, Roilides E, Groll AH et al. Infectious complications in pediatric cancer patients. In : Pizzo PA, Poplack DG, eds. Principles and practice of pediatric oncology, 5th edn. Philadelphia, PA : Lippincott Williams & Wilkins, 2006 : 1269 329.
2. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005 40 (Suppl. 4 S240 5.
3. Timmer-Bonte JN, de Boo TM, Smit HJ et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 2005 23 : 7974 84.
4. Wicki S, Keisker A, Aebi C et al. Risk prediction of fever in neutropenia in children with cancer: a step towards individually tailored supportive therapy? Pediatr Blood Cancer 2008 51 : 778 83.
5. Neth OW, Bajaj-Elliott M, Turner MW et al. Susceptibility to infection in patients with neutropenia: the role of the innate immune system. Br J Haematol 2005 129 : 713 22.
6. Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis 2003 37 : 1496 505.
7. Sorensen R, Thiel S, Jensenius JC. Mannan-binding-lectin-associated serine proteases, characteristics and disease associations. Springer Semin Immunopathol 2005 27 : 299 319. (Pubitemid 41639883)
8. Walport MJ. Complement. First of two parts. N Engl J Med 2001 344 : 1058 66.
9. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway - its role in innate immunity and evolution. Immunol Rev 2004 198 : 185 202. (Pubitemid 38406944)
10. Holmskov U, Thiel S, Jensenius JC. Collectins and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol 2003 21 : 547 78.
11. Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol 2007 44 : 3875 88.
12. Matsushita M, Kuraya M, Hamasaki N et al. Activation of the lectin complement pathway by H-ficolin (Hakata antigen). J Immunol 2002 168 : 3502 6.
13. Peterslund NA, Koch C, Jensenius JC et al. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001 358 : 637 8.
14. Neth O, Hann I, Turner MW et al. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 2001 358 : 614 18.
15. Klein NJ. Mannose-binding lectin: do we need it? Mol Immunol 2005 42 : 919 24.
16. Schlapbach LJ, Aebi C, Otth M et al. Serum levels of mannose-binding lectin and the risk of fever in neutropenia pediatric cancer patients. Pediatr Blood Cancer 2007 49 : 11 16. (Pubitemid 46847063)
17. Sugimoto R, Yae Y, Akaiwa M et al. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem 1998 273 : 20721 7.
18. Munthe-Fog L, Hummelshoj T, Ma YJ et al. Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. Mol Immunol 2008 45 : 2660 6.
19. Klein NJ, Kilpatrick DC. Is there a role for mannan/mannose-binding lectin (MBL) in defence against infection following chemotherapy for cancer? Clin Exp Immunol 2004 138 : 202 4.
20. Kilpatrick DC, McLintock LA, Allan EK et al. No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infections. Clin Exp Immunol 2003 134 : 279 84.
21. Ammann RA, Hirt A, Ridolfi Lüthy A et al. Predicting bacteremia in children with fever and chemotherapy-induced neutropenia. Pediatr Infect Dis J 2004 23 : 61 7.
22. Kern WV, Cometta A, de Bock R et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999 341 : 312 18.
23. Krarup A, Sorensen UB, Matsushita M, Jensenius JC, Thiel S. Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, L-ficolin, and H-ficolin. Infect Immun 2005 73 : 1052 60.
24. Colley KJ, Beranek MC, Baenziger JU. Purification and characterization of the core-specific lectin from human serum and liver. Biochem J 1988 256 : 61 8.
25. Altman DG. Practical statistics for medical research. London : Chapman & Hall, 1991.
26. Byar DP. Identification of prognostic factors. In : Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer clinical trial methods in practice. Oxford : Oxford Medical Publications, 1988 : 423 43.
27. Schlapbach LJ, Aebi C, Otth M et al. Deficiency of mannose-binding lectin-associated serine protease-2 associated with increased risk of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J 2007 26 : 989 94.
28. Roos A, Garred P, Wildenberg M et al. Antibody-mediated activation of the classical pathway of complement may compensate for mannose-binding lectin deficiency. Eur J Immunol 2004 34 : 2589 98.
29. Granell M, Urbano-Ispizua A, Suarez B et al. Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol 2006 34 : 1435 41.
30. Hummelshoj T, Fog LM, Madsen HO et al. Comparative study of the human ficolins reveals unique features of Ficolin-3 (Hakata antigen). Mol Immunol 2008 45 : 1623 32.
31. Aoyagi Y, Adderson EE, Min JG et al. Role of L-ficolin/mannose-binding lectin-associated serine protease complexes in the opsonophagocytosis of type III group B streptococci. J Immunol 2005 174 : 418 25.
32. Ng PM, Le Saux A, Lee CM et al. C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. EMBO J 2007 26 : 3431 40.
33. Ytting H, Christensen IJ, Thiel S et al. Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise. Scand J Immunol 2007 66 : 458 64.
34. Nielsen RG, Vind I, Munkholm P et al. Genetic polymorphisms of mannan binding lectin (MBL), serum levels of MBL, the MBL associated serine protease and H-ficolin in patients with Crohn's disease. Gut 2007 56 : 311 12.
35. Akaiwa M, Yae Y, Sugimoto R et al. Hakata antigen, a new member of the ficolin/opsonin p35 family, is a novel human lectin secreted into bronchus/alveolus and bile. J Histochem Cytochem 1999 47 : 777 86.
36. Kuraya M, Matsushita M, Endo Y et al. Expression of H-ficolin/Hakata antigen, mannose-binding lectin-associated serine protease (MASP)-1 and MASP-3 by human glioma cell line T98G. Int Immunol 2003 15 : 109 17.
37. Altman DG, Lausen B, Sauerbrei W et al. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994 86 : 829 33.
38. Mullen CA. Which children with fever and neutropenia can be safely treated as outpatients? Br J Haematol 2001 112 : 832 7.
39. Ammann RA, Simon A, de Bont ES. Low risk episodes of fever and neutropenia in pediatric oncology: is outpatient oral antibiotic therapy the new gold standard of care? Pediatr Blood Cancer 2005 45 : 244 7.
40. Klastersky J, Paesmans M, Georgala A et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006 24 : 4129 34.